Pharmaceutical

Golgi and Breye partner to develop P2X7 receptor antagonist programme

Golgi Neurosciences has joined forces with Breye Therapeutics for the development of a P2X7 receptor antagonist programme.

Jul 25, 2023 - 20:00
Golgi and Breye partner to develop P2X7 receptor antagonist programme
Golgi Neurosciences has joined forces with Breye Therapeutics for the development of a P2X7 receptor antagonist programme.
Read the original article

Tags:

Previous Article

EMA CHMP provides positive opinion for ViiV’s cabotegravir

Next Article

Gilead and Cognizant expand deal to expedite digital transformation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Goldman Sachs launches $650 million fund for life sciences investments

STAT+: Goldman Sachs launches $650 million fund for lif...

Jan 4, 2024

STAT+: CRISPR? Nah. A new startup bets on an old approach to gene editing

STAT+: CRISPR? Nah. A new startup bets on an old approa...

Mar 19, 2023

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarc...

Jun 20, 2024